New drugs for the treatment of human parasitic protozoa;Les antiprotozoaires: Des médicaments orphelins en médecine humaine?

Parassitologia

Volumn 46, Issue 1-2, 2004, Pages 81-84

  Dupouy Camet, J ^a  

^a Univ René Descartes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 NITROIMIDAZOLE DERIVATIVE; AMPHOTERICIN; ANTIMALARIAL AGENT; ANTIMETABOLITE; ANTIPROTOZOAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE PLUS PROGUANIL; DNA; FERREDOXIN REDUCTASE; FREE RADICAL; MEPACRINE; MILTEFOSINE; NITAZOXANIDE; OXIDOREDUCTASE; PYRIMETHAMINE SULFADIAZINE; SECNIDAZOLE; TINIDAZOLE; UNCLASSIFIED DRUG;

AMOEBA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; APICOMPLEXA; APICOPLAST; AUSTRALIA; BIOSYNTHESIS; CONFERENCE PAPER; DRUG COST; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG TOLERABILITY; GIARDIA; HEATING; HELMINTH; HUMAN; LEISHMANIASIS; MALARIA; MUTAGENICITY; PREGNANCY; PROTOZOAL INFECTION; PROTOZOON; TARGET CELL; TERATOGENICITY; TOXOPLASMOSIS; UNITED STATES; VISCERAL LEISHMANIASIS; ADULT; ANIMAL; CHILD; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG RESISTANCE; DRUG SCREENING; FEMALE; INTESTINE INFECTION; ISOLATION AND PURIFICATION; MALE; PARASITOLOGY; PREGNANCY COMPLICATION; REVIEW;

APICOMPLEXA; CANIS FAMILIARIS; GIARDIA; HETEROLOBOSEA; PROTOZOA; VERMES;

ADULT; ANIMALS; ANTIMALARIALS; ANTIPROTOZOAL AGENTS; CHILD; DRUG DESIGN; DRUG EVALUATION; DRUG RESISTANCE; FEMALE; HUMANS; INTESTINAL DISEASES, PARASITIC; LEISHMANIASIS; MALARIA; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTOZOAN INFECTIONS; TOXOPLASMOSIS;

EID: 4844223096     PISSN: 00482951     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Abboud P, Lemee V, Gargala G, Brasseur P, Ballet JJ, Borsa-Lebas F, Caron F, Favennec L (2001). Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 32: 1792-1794.
2. AAVV Special issue (2003). Drugs for the control of parasitic diseases. Trends in Parasitology 19: 477-543.
3. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P (2002). Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. The Lancet 360: 1375-1380.
4. Bau P, Bolard J, Dupouy-Camet J (2003). Heated amphotericin to treat leishmaniasis. Lancet Infect Dis 3: 188.
5. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD (2004). Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 38: 217-21.
6. Biagini GA, O'Neill PM, Nzila A, Ward SA, Bray PG (2003). Antimalarial chemotherapy: young guns or back to the future? Trends Parasitol 19:479-87.
7. Croft SL, Coombs GH (2003). Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-8.
8. Danis M, Bricaire F (2003). The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria Fundam Clin Pharmacol 17:155-60.
9. Djurkovic-Djakovic O, Milenkovic V, Nikolic A, Bobic B, Grujic J (2002). Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J Antimicrob Chemother 50: 981-987.
10. Dupouy-Camet J, (1994). Drug Investigation 8 suppl.1: 35-46.
11. Dupouy-Camet J, Yera H, Tourte-Schaeffer C (2003) Problems in prescribing malaria chemoprophylaxis for travelers. Fundam Clin Pharmacol 17:161-169.
12. Gilles HM, Hoffman PS (2002). Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 18: 95-97.
13. Gozalbes R, Brun-Pascaud M, Garcia-Domenech R, Galvez J, Girard PM, Doucet JP, Derouin F (2000). Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques. Antimicrob Agents Chemother 44: 2771-2776.
14. Gormley PD, Pavesio CE, Minnasian D, Lightman S (1998). Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol Vis Sci 39: 1171-1175.
15. Gramiccia M, Gradoni L, Orsini S (1992). Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 86:613-620.
16. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD (2002). Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda Lancet Infect Dis 2: 494-501.
17. Jones-Brando L, Torrey EF, Yolken R (2003). Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 62: 237-244.
18. Holfels E, McAuley J, Mack D, Milhous WK, McLeod R (1994). In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii. Antimicrob Agents Chemother 38: 1392-1396.
19. Lapierre J, Bougnoux ME, Dupouy-Camet J, Heyer F (1985). Value of mepacrine in the treatment of resistant giardiasis. Presse Med 14:1667.
20. Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Norton J, Kremsner PG. Malaria chemoprophylaxis with tafenoquine: a randomised study. The Lancet 355: 2041-2045.
21. Minodier P, Retornaz K, Horelt A, Garnier JM (2003). Liposomal. amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundam Clin Pharmacol 17: 183-188.
22. Molina JM, Chastang C, Goguel J, Michiels JF, Sarfati C, Desportes-Livage I, Norton J, Derouin F, Modai J (1998). Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 177: 1373-1377.
23. Molina JM, Tourneur M, Sarfati C, Chevret S, de Gouvello A, Gobert JG, Balkan S, Derouin F (2002). Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 346: 1963-1969.
24. Pearson PA, Piracha AR, Sen HA, Jaffe GJ (1999). Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 106: 148-153.
25. Pengsaa K, Limkittikul K, Pojjaroen-anant C, Lapphra K, Sirivichayakul C, Wisetsing P, Nantha-aree P, Chanthavanich P (2002). Single-dose therapy for giardiasis in school-age children. Southeast Asian J Trop Med Public Health 33: 711-717.
26. Petit C, Yardley V, Gaboriau F, Bolard J, Croft SL (1999). Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani Antimicrob Agents Chemother 43: 390-392.
27. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J (2001). Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: 57-61.
28. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW (2001).Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323: 419-422.
29. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002). Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
30. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. (2002). Drug development for neglected diseases: a deficient market and a public-health policy failure. The Lancet 359: 2188-94.
31. Winstanley P (2001). Modern chemotherapeutic options for malaria. Lancet Infect Dis 1: 242-250.